Show simple item record

dc.contributor.authorLaxy, Michael
dc.contributor.authorWilson, Ed
dc.contributor.authorBoothby, Clare
dc.contributor.authorGriffin, Simon
dc.date.accessioned2017-08-22T10:19:37Z
dc.date.available2017-08-22T10:19:37Z
dc.date.issued2017-12
dc.identifier.issn1098-3015
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/266711
dc.description.abstractBACKGROUND: There is uncertainty about the cost effectiveness of early intensive treatment versus routine care in individuals with type 2 diabetes detected by screening. OBJECTIVES: To derive a trial-informed estimate of the incremental costs of intensive treatment as delivered in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care-Europe (ADDITION) trial and to revisit the long-term cost-effectiveness analysis from the perspective of the UK National Health Service. METHODS: We analyzed the electronic primary care records of a subsample of the ADDITION-Cambridge trial cohort (n = 173). Unit costs of used primary care services were taken from the published literature. Incremental annual costs of intensive treatment versus routine care in years 1 to 5 after diagnosis were calculated using multilevel generalized linear models. We revisited the long-term cost-utility analyses for the ADDITION-UK trial cohort and reported results for ADDITION-Cambridge using the UK Prospective Diabetes Study Outcomes Model and the trial-informed cost estimates according to a previously developed evaluation framework. RESULTS: Incremental annual costs of intensive treatment over years 1 to 5 averaged £29.10 (standard error = £33.00) for consultations with general practitioners and nurses and £54.60 (standard error = £28.50) for metabolic and cardioprotective medication. For ADDITION-UK, over the 10-, 20-, and 30-year time horizon, adjusted incremental quality-adjusted life-years (QALYs) were 0.014, 0.043, and 0.048, and adjusted incremental costs were £1,021, £1,217, and £1,311, resulting in incremental cost-effectiveness ratios of £71,232/QALY, £28,444/QALY, and £27,549/QALY, respectively. Respective incremental cost-effectiveness ratios for ADDITION-Cambridge were slightly higher. CONCLUSIONS: The incremental costs of intensive treatment as delivered in the ADDITION-Cambridge trial were lower than expected. Given UK willingness-to-pay thresholds in patients with screen-detected diabetes, intensive treatment is of borderline cost effectiveness over a time horizon of 20 years and more.
dc.description.sponsorshipADDITION-Cambridge was supported by the Wellcome Trust (grant reference No G061895) the Medical Research Council (grant reference no: G0001164), National Health Service R&D support funding (including the Primary Care Research and Diabetes Research Networks), and the National Institute for Health Research. We received an unrestricted grant from University of Aarhus, Denmark, to support the ADDITION-Cambridge trial. Bio-Rad provided equipment to undertake capillary glucose screening by HbA1c in general practice. SG is a National Institute for Health Research (NIHR) Senior Investigator. The Primary Care Unit is supported by NIHR Research funds. SJG received support from the Department of Health NIHR Programme Grant funding scheme (RP-PG-0606-1259).
dc.format.mediumPrint-Electronic
dc.languageeng
dc.language.isoen
dc.publisherElsevier BV
dc.subjectHumans
dc.subjectDiabetes Mellitus, Type 2
dc.subjectMass Screening
dc.subjectLinear Models
dc.subjectProspective Studies
dc.subjectQuality-Adjusted Life Years
dc.subjectTime Factors
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectCost-Benefit Analysis
dc.subjectHealth Care Costs
dc.subjectPrimary Health Care
dc.subjectFemale
dc.subjectMale
dc.subjectUnited Kingdom
dc.titleIncremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data.
dc.typeArticle
prism.endingPage1298
prism.issueIdentifier10
prism.publicationDate2017
prism.publicationNameValue Health
prism.startingPage1288
prism.volume20
dc.identifier.doi10.17863/CAM.12784
dcterms.dateAccepted2017-05-28
rioxxterms.versionofrecord10.1016/j.jval.2017.05.018
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.licenseref.startdate2017-12
dc.contributor.orcidWilson, Ed [0000-0002-8369-1577]
dc.contributor.orcidBoothby, Clare [0000-0001-9396-8333]
dc.contributor.orcidGriffin, Simon [0000-0002-2157-4797]
dc.identifier.eissn1524-4733
rioxxterms.typeJournal Article/Review
pubs.funder-project-idNETSCC (None)
pubs.funder-project-idMedical Research Council (MC_UU_12015/4)
pubs.funder-project-idNIHR Central Commissioning Facility (NIHRDH-RP-PG-0606-1259)
pubs.funder-project-idMedical Research Council (G0001164)
pubs.funder-project-idWellcome Trust (061895/Z/00/Z)
cam.issuedOnline2017-07-03
rioxxterms.freetoread.startdate2018-07-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record